{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13"],"submitter":["Du S"],"pubmed_abstract":["<h4>Background</h4>Existing research has shown that long non-coding RNA (lncRNA) MAGI2 antisense RNA3 (MAGI2-AS3) expression is significantly decreased in breast cancer tissues and can inhibit breast cancer progression. However, the relationship between MAGI2-AS3 expression levels in peripheral blood mononuclear cells (PBMCs) and breast cancer remains unclear. This study aimed to explore the clinical significance of MAGI2-AS3 expression in PBMCs for diagnosing breast cancer and predicting patient prognosis.<h4>Methods</h4>Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to detect MAGI2-AS3 expression in PBMCs from healthy donors and breast cancer patients. The chi-square test analyzed the associations between MAGI2-AS3 expression and breast cancer clinicopathological parameters. The Kaplan-Meier method evaluated the impact of MAGI2-AS3 on patients' overall survival (OS), and receiver operating characteristic (ROC) analysis assessed its diagnostic accuracy for breast cancer.<h4>Results</h4>MAGI2-AS3 expression was significantly downregulated in breast cancer patients' PBMCs compared to the control group. Its expression decreased with the advancement of tumor-node-metastasis (TNM) stage and elevation of pathological grade, and was remarkably lower in patients with distant metastasis (DM). Low MAGI2-AS3 expression in PBMCs was correlated with shorter OS. ROC curve analysis showed that MAGI2-AS3 in PBMCs had good diagnostic accuracy.<h4>Conclusion</h4>MAGI2-AS3 expression in breast cancer patients' PBMCs is reduced and negatively correlated with patient outcomes. Thus, it has the potential to be a valuable biomarker for breast cancer diagnosis and prognostic evaluation."],"journal":["PeerJ"],"pagination":["e19694"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12273699"],"repository":["biostudies-literature"],"pubmed_title":["The lncRNA MAGI2-AS3 in peripheral blood mononuclear cells: a valuable biomarker for diagnosis and prognosis prediction of breast cancer."],"pmcid":["PMC12273699"],"pubmed_authors":["Yang H","Yang Y","Liu K","Du S"],"additional_accession":[]},"is_claimable":false,"name":"The lncRNA MAGI2-AS3 in peripheral blood mononuclear cells: a valuable biomarker for diagnosis and prognosis prediction of breast cancer.","description":"<h4>Background</h4>Existing research has shown that long non-coding RNA (lncRNA) MAGI2 antisense RNA3 (MAGI2-AS3) expression is significantly decreased in breast cancer tissues and can inhibit breast cancer progression. However, the relationship between MAGI2-AS3 expression levels in peripheral blood mononuclear cells (PBMCs) and breast cancer remains unclear. This study aimed to explore the clinical significance of MAGI2-AS3 expression in PBMCs for diagnosing breast cancer and predicting patient prognosis.<h4>Methods</h4>Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to detect MAGI2-AS3 expression in PBMCs from healthy donors and breast cancer patients. The chi-square test analyzed the associations between MAGI2-AS3 expression and breast cancer clinicopathological parameters. The Kaplan-Meier method evaluated the impact of MAGI2-AS3 on patients' overall survival (OS), and receiver operating characteristic (ROC) analysis assessed its diagnostic accuracy for breast cancer.<h4>Results</h4>MAGI2-AS3 expression was significantly downregulated in breast cancer patients' PBMCs compared to the control group. Its expression decreased with the advancement of tumor-node-metastasis (TNM) stage and elevation of pathological grade, and was remarkably lower in patients with distant metastasis (DM). Low MAGI2-AS3 expression in PBMCs was correlated with shorter OS. ROC curve analysis showed that MAGI2-AS3 in PBMCs had good diagnostic accuracy.<h4>Conclusion</h4>MAGI2-AS3 expression in breast cancer patients' PBMCs is reduced and negatively correlated with patient outcomes. Thus, it has the potential to be a valuable biomarker for breast cancer diagnosis and prognostic evaluation.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2025-08-23T03:09:17.869Z","creation":"2025-08-23T03:09:17.869Z"},"accession":"S-EPMC12273699","cross_references":{"pubmed":["40687762"],"doi":["10.7717/peerj.19694"]}}